UnitedHealth Group Incorporated (UNH) is gearing up to announce its third-quarter 2024 financial results on October 15th, before the market opens. Wall Street analysts are expecting the company to report earnings of $7.02 per share on revenues of $99.6 billion.
While several factors point towards a strong performance, including growing premiums, expansion of its commercial membership base, and the continued success of its Optum business, some headwinds could impact profitability. Elevated expenses, a decline in Medicaid memberships, and the aftereffects of a cyber-attack on its Change Healthcare business are expected to partially offset these positive drivers.
UnitedHealth has a solid track record of exceeding earnings estimates, having surpassed expectations in each of the last four quarters. However, current market conditions and the company’s valuation raise questions about its ability to beat estimates this time around.
Key Drivers of Q3 Results:
*
Premium Growth:
Expansion in commercial memberships is expected to fuel premium revenue growth, with analysts forecasting a 6.1% year-over-year increase. Optum Health and the health benefits divisions are anticipated to contribute significantly to this growth.*
Optum’s Impact:
Optum’s service and product revenues are expected to see notable growth, driven by increased value-based care arrangements, technology-enabled offerings, and expansion in specialty and community-based pharmacy services. However, the cyber-attack on Change Healthcare in the first quarter is expected to negatively impact Optum’s profitability in the third quarter.*
Membership Trends:
While commercial and Medicare Advantage memberships are projected to grow, Medicaid memberships are expected to decline. International memberships are also forecast to see a substantial drop, impacting overall membership growth.*
Rising Expenses:
Increased healthcare utilization, particularly in the Medicare Advantage space, is anticipated to elevate overall expenses and potentially impact margins. Higher costs of products sold are also expected to contribute to margin pressure.Valuation and Outlook:
UnitedHealth’s stock has performed well year-to-date, outperforming the broader healthcare industry. However, the company’s valuation currently appears stretched compared to its peers. Its forward price-to-earnings ratio is above its five-year median and the industry average, suggesting that the stock may be priced for perfection.
Despite these challenges, UnitedHealth’s long-term growth prospects remain strong. The company’s diversified portfolio, strategic growth initiatives, and commitment to shareholder returns offer positive long-term potential. However, investors should carefully consider the near-term headwinds and the company’s valuation before making any investment decisions.
Investor Takeaway:
While UnitedHealth’s long-term outlook is positive, the current market conditions and the company’s valuation may make this a less attractive entry point for investors. It might be wise to wait for a more favorable opportunity to buy into the stock. Current shareholders may want to consider locking in profits as the stock appears overvalued and short-term growth potential may be limited.
